June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
The MOSAIC Study: A clinical and humanistic burden of illness study among patients with geographic atrophy (GA) and their caregivers in the United States (US) and Canada (CA)
Author Affiliations & Notes
  • Jaclyn Quilantan
    Apellis Pharmaceuticals Inc, Waltham, Massachusetts, United States
  • Chris Réaume
    Apellis Pharmaceuticals Inc, Waltham, Massachusetts, United States
  • Winfried Amoaku
    University of Nottingham, Nottingham, United Kingdom
  • Stéphane Quéré
    Thread, Tustin, California, United States
  • Manal M’Hari
    Thread, Tustin, California, United States
  • Julia Carpenter-Conlin
    Apellis Pharmaceuticals Inc, Waltham, Massachusetts, United States
  • Sujata Sarda
    Apellis Pharmaceuticals Inc, Waltham, Massachusetts, United States
  • Daniel Jones
    Apellis Pharmaceuticals Inc, Waltham, Massachusetts, United States
  • Sophie J Bakri
    Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Jared Nielsen
    Wolfe Eye Clinic PC, Marshalltown, Iowa, United States
  • Footnotes
    Commercial Relationships   Jaclyn Quilantan Apellis Pharmaceuticals Inc, Code E (Employment); Chris Réaume Apellis Pharmaceuticals Inc., Code E (Employment); Winfried Amoaku Abbvie, Allergan, Novartis, Roche, Code C (Consultant/Contractor), Bayer, Boerhinger Ingelheim, Code F (Financial Support), Abbvie, Novartis, Roche, Bioeq, Code R (Recipient), Convention for Biomedical Research Ghana, Code S (non-remunerative); Stéphane Quéré None; Manal M’Hari None; Julia Carpenter-Conlin Apellis Pharmaceuticals Inc., Code E (Employment); Sujata Sarda Apellis Pharmaceuticals Inc., Code E (Employment); Daniel Jones Apellis Pharmaceuticals Inc, Code E (Employment); Sophie Bakri Adverum, Apellis, Eyepoint, ilumen, Iveric Bio, Genentech, Pixium, Regenxbio, Code C (Consultant/Contractor), Revana, Code R (Recipient); Jared Nielsen Genentech, Regeneron, Ivenic Bio, Novartis, Kodiak Scientific, Code C (Consultant/Contractor), Genentech, Regeneron, Ivenic Bio, Code R (Recipient)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3722. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jaclyn Quilantan, Chris Réaume, Winfried Amoaku, Stéphane Quéré, Manal M’Hari, Julia Carpenter-Conlin, Sujata Sarda, Daniel Jones, Sophie J Bakri, Jared Nielsen; The MOSAIC Study: A clinical and humanistic burden of illness study among patients with geographic atrophy (GA) and their caregivers in the United States (US) and Canada (CA). Invest. Ophthalmol. Vis. Sci. 2023;64(8):3722.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To characterize the burden of GA in patients and caregivers in the US and CA

Methods : We conducted a survey in the US and CA with 149 GA patients (102 in the US, 47 in CA) and 148 unpaid caregivers of GA patients (102 in the US, 46 in CA).

Results : There was a higher proportion of male patients in CA than in the US (62% vs. 43%), and the mean (standard deviation, SD) age was lower in the US (68 [4]) than in CA (73 [5]). Patients were mostly retired (77% in the US, 81% in CA). Mean (SD) time from GA diagnosis was 6.3 (5.2) and 5.3 (3.6) years in the US and CA, respectively. Visual changes due to GA were reported in both eyes by 43% of US patients and 47% of CA patients. Patients reported receiving help from children (41% in the US, 34% in CA), partners (39% in the US, 47% in CA), and/or other family members (39% in the US, 32% in CA). Mean (SD) NEI VFQ-39 composite scores were comparable in both countries (44.6 [20.2] in the US and 48.3 [21.3] in CA), indicating similar vision-related quality of life. More US patients reported needing daily help (68%) or a change in their living situation because of GA (38%) than did CA patients (38% and 28%, respectively). 86% of US patients and 72% of CA patients did not drive; 95% and 97% of non-drivers gave up driving because of their eyesight in the US and CA, respectively.
There was a higher proportion of male caregivers in CA than in the US (61% vs. 47%), and the mean (SD) age was similar in both countries (46 [15] in the US and 44 [11] in CA). In the US, caregivers mostly reported caring for their partner (37%) or a parent (30%) while in CA they mostly reported caring for their parent (65%) or a grandparent (26%). 63% of CA caregivers were categorized as having moderate to severe burden vs. only 15% of US caregivers [per Zarit Burden Interview (ZBI)]. 44% and 93% of US and CA caregivers were employed, respectively; time missed from work in the previous week due to caregiver responsibilities was similar (mean [SD] of 3 [6] in the US and 3 [3] hours in CA).
US dyad data (n=93) showed that the burden of patients and caregivers was moderately correlated with a correlation of -0.63 between NEI VFQ-39 composite score and ZBI score.

Conclusions : These results highlight the substantial burden of GA on patients and their caregivers in the US and CA.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×